UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 590

Sortiert nach

Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials

Diabetes care, 2018-12, Vol.41 (12), p.2560-2569

2018

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial

Diabetes care, 2016-11, Vol.39 (11), p.1972-1980

2016

Link zum Volltext

Verfügbarkeit prüfen

More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial

Diabetes care, 2018-10, Vol.41 (10), p.2147-2154

2018

Link zum Volltext

Verfügbarkeit prüfen

DPP-4 Inhibitor-Related Pancreatitis: Rare but Real

Diabetes care, 2017-02, Vol.40 (2), p.161-163

2017

Link zum Volltext

Verfügbarkeit prüfen

Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET)

Diabetes, obesity & metabolism, 2018-03, Vol.20 (3), p.520-529

2018

Link zum Volltext

Verfügbarkeit prüfen

Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial

European heart journal, 2013-10, Vol.34 (40), p.3137-3144

2013

Link zum Volltext

Verfügbarkeit prüfen

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

The Lancet (British edition), 2009-07, Vol.374 (9683), p.39-47

2009

Link zum Volltext

Verfügbarkeit prüfen

Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors

Diabetes care, 2015-09, Vol.38 (9), p.1638-1642

2015

Link zum Volltext

Verfügbarkeit prüfen

Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study

Diabetes care, 2015-03, Vol.38 (3), p.412-419

2015

Link zum Volltext

Verfügbarkeit prüfen

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial

The Lancet (British edition), 2012-08, Vol.380 (9840), p.475-483

2012

Link zum Volltext

Verfügbarkeit prüfen

Kidney Disease End Points in a Pooled Analysis of Individual Patient–Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes

American journal of kidney diseases, 2015-09, Vol.66 (3), p.441-449

2015

Link zum Volltext

Verfügbarkeit prüfen

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes

Diabetes care, 2015-07, Vol.38 (7), p.1181-1188

2015

Link zum Volltext

Verfügbarkeit prüfen

Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial

Diabetes care, 2016-08, Vol.39 (8), p.1318-1328

2016

Link zum Volltext

Verfügbarkeit prüfen

Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum

Diabetes care, 2016-07, Vol.39 (7), p.1186-1201

2016

Link zum Volltext

Verfügbarkeit prüfen

Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial

Pain (Amsterdam), 2004-08, Vol.110 (3), p.628-638

2004

Link zum Volltext

Verfügbarkeit prüfen

Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION‐7 randomized study

Diabetes, obesity & metabolism, 2018-07, Vol.20 (7), p.1602-1614

2018

Link zum Volltext

Verfügbarkeit prüfen

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

The Lancet (British edition), 2012-04, Vol.379 (9825), p.1498-1507

2012

Link zum Volltext

Verfügbarkeit prüfen

FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later

Diabetes, obesity & metabolism, 2019-05, Vol.21 (5), p.1073-1078

2019

Link zum Volltext

Verfügbarkeit prüfen

Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea

Diabetes care, 2005-05, Vol.28 (5), p.1083-1091

2005

Link zum Volltext

Verfügbarkeit prüfen

Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®)

Diabetes & vascular disease research, 2015-05, Vol.12 (3), p.164-174

2015

Link zum Volltext

Verfügbarkeit prüfen

Response to Comment on Rosenstock et al. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Diabetes Care 2020;43:2509-2518

Diabetes care, 2021-11, Vol.44 (11), p.e196-e197

Rosenstock, Julio

2021

Link zum Volltext

Verfügbarkeit prüfen

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study

The lancet. Diabetes & endocrinology, 2014-04, Vol.2 (4), p.289-297

2014

Link zum Volltext

Verfügbarkeit prüfen

Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials

Cardiovascular diabetology, 2022-09, Vol.21 (1), p.1-172, Article 172

2022

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial

BMC neurology, 2008-09, Vol.8 (1), p.33-33, Article 33

2008

Link zum Volltext

Verfügbarkeit prüfen

Colesevelam HCl Improves Glycemic Control and Reduces LDL Cholesterol in Patients With Inadequately Controlled Type 2 Diabetes on Sulfonylurea-Based Therapy

Diabetes care, 2008-08, Vol.31 (8), p.1479-1484

2008

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 590

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(517)
Mit Volltextzugriff
(546)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(310)
Life Sciences & Biomedicine
(309)
Humans
(266)
Diabetes
(254)
Endocrinology & Metabolism
(232)
Diabetes Mellitus, Type 2 - Drug Therapy
(187)
Female
(172)
Male
(170)
Diabetes Mellitus
(166)
Middle Aged
(156)
Insulin
(134)
Adult
(119)
Hypoglycemia
(112)
Aged
(110)
Hypoglycemic Agents - Therapeutic Use
(110)
Treatment Outcome
(103)
Type 2 Diabetes
(102)
Hypoglycemic Agents - Administration & Dosage
(96)
Clinical Trials
(94)
Double-Blind Method
(88)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(11)

Menü

Weitere Dienste

Einstellungen

Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials

Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial

More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial

DPP-4 Inhibitor-Related Pancreatitis: Rare but Real

Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET)

Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors

Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial

Kidney Disease End Points in a Pooled Analysis of Individual Patient–Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes

Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial

Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum

Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial

Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION‐7 randomized study

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later

Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea

Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®)

Response to Comment on Rosenstock et al. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Diabetes Care 2020;43:2509-2518

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study

Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials

Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial

Colesevelam HCl Improves Glycemic Control and Reduces LDL Cholesterol in Patients With Inadequately Controlled Type 2 Diabetes on Sulfonylurea-Based Therapy

Suchergebnisse filtern